UBS Group
TXG icon

UBS Group’s 10x Genomics TXG Stock Holding History

UBS Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$893K – 8420
2020
Q2 		$893K Buy
+10,000
New +$779K ﹤0.01% 3609

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's TXG Position: Q1 2026 in Review

UBS Group reduced its 10x Genomics (TXG) stake by 43% in Q1 2026, selling an estimated $7.32M and leaving 494,762 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3273.

UBS Group first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $14M in Q4 2025. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • UBS Group held 494,762 shares of 10x Genomics worth $10.5M as of Q1 2026.
  • UBS Group sold 366,238 10x Genomics shares in Q1 2026, an estimated $7.32M.
  • 10x Genomics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3273 holding.
  • UBS Group first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • UBS Group's 10x Genomics position peaked at $14M in Q4 2025.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.